KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Free Cash Flow (2016 - 2025)

Gilead Sciences' Free Cash Flow history spans 17 years, with the latest figure at $3.1 billion for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 10.4% year-over-year to $3.1 billion; the TTM value through Dec 2025 reached $9.5 billion, down 8.24%, while the annual FY2025 figure was $9.5 billion, 8.24% down from the prior year.
  • Free Cash Flow reached $3.1 billion in Q4 2025 per GILD's latest filing, down from $4.0 billion in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $4.2 billion in Q3 2024 to a low of $720.0 million in Q2 2025.
  • Average Free Cash Flow over 5 years is $2.3 billion, with a median of $2.2 billion recorded in 2021.
  • The largest YoY upside for Free Cash Flow was 155.24% in 2024 against a maximum downside of 45.66% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at $3.0 billion in 2021, then decreased by 21.74% to $2.4 billion in 2022, then fell by 18.11% to $2.0 billion in 2023, then skyrocketed by 44.73% to $2.8 billion in 2024, then increased by 10.4% to $3.1 billion in 2025.
  • Per Business Quant, the three most recent readings for GILD's Free Cash Flow are $3.1 billion (Q4 2025), $4.0 billion (Q3 2025), and $720.0 million (Q2 2025).